JP2023541217A - 抗IgE改変抗体及びその適用 - Google Patents

抗IgE改変抗体及びその適用 Download PDF

Info

Publication number
JP2023541217A
JP2023541217A JP2023501419A JP2023501419A JP2023541217A JP 2023541217 A JP2023541217 A JP 2023541217A JP 2023501419 A JP2023501419 A JP 2023501419A JP 2023501419 A JP2023501419 A JP 2023501419A JP 2023541217 A JP2023541217 A JP 2023541217A
Authority
JP
Japan
Prior art keywords
amino acid
binding protein
antigen
protein according
acid mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2023501419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541217A5 (cg-RX-API-DMAC7.html
Inventor
デン,スージュン
グー,チュンイン
リウ,シァオウー
ツァオ,シャオダン
リウ,ペイペイ
ジャン,ジエンジエン
パン,ジョンゾン
シャオ,ジェン
ワン,シュエピン
グオ,ハイピン
Original Assignee
シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド
チアンシー ジェミンケア グループ カンパニー、リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド, チアンシー ジェミンケア グループ カンパニー、リミテッド filed Critical シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド
Publication of JP2023541217A publication Critical patent/JP2023541217A/ja
Publication of JP2023541217A5 publication Critical patent/JP2023541217A5/ja
Priority to JP2026017958A priority Critical patent/JP2026071342A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023501419A 2020-07-10 2021-07-09 抗IgE改変抗体及びその適用 Ceased JP2023541217A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026017958A JP2026071342A (ja) 2020-07-10 2026-02-05 抗IgE改変抗体及びその適用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010663029 2020-07-10
CN202010663029.3 2020-07-10
CN202110750959.7 2021-07-01
CN202110750959 2021-07-01
PCT/CN2021/105620 WO2022007965A1 (zh) 2020-07-10 2021-07-09 一种抗IgE的工程化抗体及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026017958A Division JP2026071342A (ja) 2020-07-10 2026-02-05 抗IgE改変抗体及びその適用

Publications (2)

Publication Number Publication Date
JP2023541217A true JP2023541217A (ja) 2023-09-29
JP2023541217A5 JP2023541217A5 (cg-RX-API-DMAC7.html) 2024-07-17

Family

ID=79552269

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023501419A Ceased JP2023541217A (ja) 2020-07-10 2021-07-09 抗IgE改変抗体及びその適用
JP2026017958A Pending JP2026071342A (ja) 2020-07-10 2026-02-05 抗IgE改変抗体及びその適用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026017958A Pending JP2026071342A (ja) 2020-07-10 2026-02-05 抗IgE改変抗体及びその適用

Country Status (11)

Country Link
US (1) US20230250191A1 (cg-RX-API-DMAC7.html)
EP (1) EP4180454A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023541217A (cg-RX-API-DMAC7.html)
KR (1) KR20230042030A (cg-RX-API-DMAC7.html)
CN (1) CN116018352A (cg-RX-API-DMAC7.html)
AU (1) AU2021306786A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000400A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185192A1 (cg-RX-API-DMAC7.html)
IL (1) IL299747A (cg-RX-API-DMAC7.html)
TW (1) TWI896700B (cg-RX-API-DMAC7.html)
WO (1) WO2022007965A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318098A (en) 2022-07-01 2025-02-01 Alk Abell? As IGE-FCER pushers
CN116143932B (zh) * 2022-12-07 2025-02-11 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510211A (ja) * 1997-07-02 2002-04-02 ジェネンテク,インコーポレイテッド 改良抗IgE抗体及びポリペプチドの改良方法
JP2011523350A (ja) * 2008-03-31 2011-08-11 ジェネンテック, インコーポレイテッド 喘息の治療及び診断のための組成物及び方法
JP2021512856A (ja) * 2018-02-09 2021-05-20 ジェネンテック, インコーポレイテッド マスト細胞媒介性炎症性疾患の治療法及び診断法
JP2021523117A (ja) * 2018-05-04 2021-09-02 アラコス インコーポレイテッド 慢性蕁麻疹を処置するための方法および組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1260521B1 (en) 1991-08-14 2007-11-21 Genentech Inc. Immunoglobulin variants for specific Fc epsilon receptors
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
US20180273626A1 (en) * 2015-09-11 2018-09-27 The Board Of Trustees Of The Leland Stanford Junio University Omalizumab resistant ige variants and their use in anti-ige therapy
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP4342541A3 (en) * 2017-04-07 2024-07-03 Kookmin University Industry Academy Cooperation Foundation Antibody fc variants for increased blood half-life

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510211A (ja) * 1997-07-02 2002-04-02 ジェネンテク,インコーポレイテッド 改良抗IgE抗体及びポリペプチドの改良方法
JP2011523350A (ja) * 2008-03-31 2011-08-11 ジェネンテック, インコーポレイテッド 喘息の治療及び診断のための組成物及び方法
JP2021512856A (ja) * 2018-02-09 2021-05-20 ジェネンテック, インコーポレイテッド マスト細胞媒介性炎症性疾患の治療法及び診断法
JP2021523117A (ja) * 2018-05-04 2021-09-02 アラコス インコーポレイテッド 慢性蕁麻疹を処置するための方法および組成物

Also Published As

Publication number Publication date
US20230250191A1 (en) 2023-08-10
EP4180454A4 (en) 2024-10-02
KR20230042030A (ko) 2023-03-27
IL299747A (en) 2023-03-01
TWI896700B (zh) 2025-09-11
JP2026071342A (ja) 2026-04-28
CN116018352A (zh) 2023-04-25
WO2022007965A1 (zh) 2022-01-13
CA3185192A1 (en) 2022-01-13
EP4180454A9 (en) 2023-07-26
EP4180454A1 (en) 2023-05-17
AU2021306786A1 (en) 2023-02-16
BR112023000400A2 (pt) 2023-03-21
TW202214703A (zh) 2022-04-16

Similar Documents

Publication Publication Date Title
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
US12043663B2 (en) Anti-TNF-alpha-antibodies and functional fragments thereof
EP3430045B1 (en) Anti-tnfalpha-antibodies and functional fragments thereof
JP7858629B2 (ja) Fgfr3抗体および使用の方法
JP2026071342A (ja) 抗IgE改変抗体及びその適用
TW202346343A (zh) 抗體
IL297638A (en) Compounds and methods targeting interleukin-34
CN112574314A (zh) 一种融合蛋白及其应用
WO2019062831A1 (zh) Il-5抗体、其抗原结合片段及医药用途
CN118459583A (zh) 抗N3pGlu淀粉样蛋白β抗体及其用途
CN116284408A (zh) 结合人muc17的抗体、其制备方法及用途
CN113366020B (zh) 抗pd-l1的新型抗体及其用途
CN109153718B (zh) 抗TNFα抗体及其功能片段
WO2022037528A1 (zh) 结合bcma的单可变结构域及抗原结合分子
JP2024509369A (ja) 抗pd-l1抗体及びその使用
WO2020239014A1 (zh) 抗cgrp抗体及其应用
TWI918239B (zh) Gdf15中和抗體及其用途
EP4293046A1 (en) Anti-pd-1 antibody and use thereof
WO2026017189A2 (zh) 抗il-31抗体、其药物组合物及用途
CN116535503A (zh) 抗生长分化因子15的抗体分子及其应用
CN114075284A (zh) Cd47结合分子及其用途
HK40001673B (en) Anti-tnfalpha-antibodies and functional fragments thereof
HK40001673A (en) Anti-tnfalpha-antibodies and functional fragments thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20260526